FLUTICASONE/UMECLIDINIUM/VILANTEROL DRY POWDER INHALER (Trelegy Ellipta®)
Clinical Indication
COPD
Comments
Reviewed by the respiratory group
Date of classification
June 2021
Do not prescribe
Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.